Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced that it has received an extension from the TSX Venture Exchange to complete its private placement of up to 16,666,667 units at $0.06 per unit, targeting $1 million in gross proceeds.
One or more closings may occur through December 30, 2024.
Voyageur specializes in developing barium and iodine APIs and aims to vertically integrate the imaging contrast agent market.